Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Administration  




2 Pharmacokinetics  




3 See also  




4 References  













Anileridine






●العربية
 ●Azərbaycanca
 ●Español
 ●فارسی
 ●Hrvatski
 ●Magyar
 ●日本語
 ●Polski
 ●Português
 ●Română
 ●Русский
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Svenska
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Anileridine
Clinical data
Trade namesLeritine
AHFS/Drugs.comMonograph
Routes of
administration		Tablets, injection
ATC code
Legal status
Legal status
  • AU: S8 (Controlled drug)
  • BR: Class A1 (Narcotic drugs)[1]
  • CA: Schedule I
  • DE: Anlage I (Authorized scientific use only)
  • US: Schedule II
    • Pharmacokinetic data
    Protein binding> 95%
    MetabolismHepatic
    Identifiers

    • Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate

    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC22H28N2O2
    Molar mass352.478 g·mol−1
    3D model (JSmol)
    Melting point83 °C (181 °F)

    • O=C(OCC)C3(c1ccccc1)CCN(CCc2ccc(N)cc2)CC3

    • InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3 checkY

    • Key:LKYQLAWMNBFNJT-UHFFFAOYSA-N checkY

     ☒NcheckY (what is this?)  (verify)

    Anileridine (trade name: Leritine) is a synthetic analgesic drug[2] and is a member of the piperidine class of analgesic agents[3] developed by Merck & Co. in the 1950s.[4] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.

    Anileridine is no longer manufactured in the US or Canada.[5] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate.[6] It is also under international control per UN treaties.

    Administration[edit]

    Astabletsorinjection.[7]

    Pharmacokinetics[edit]

    Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[8] It is mostly metabolized by the liver.

    See also[edit]

    References[edit]

    1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  • ^ Orahovats PD, Lehman EG, Chapin EW (January 1957). "Pharmacology of ethyl-1-(4-aminophenethyl)-4-phenylisonipecotate, anileridine, a new potent synthetic analgesic". The Journal of Pharmacology and Experimental Therapeutics. 119 (1): 26–34. PMID 13417056.
  • ^ Stage JT (August 1957). "Anileridine as an anesthetic agent". The Journal of the Florida Medical Association. Florida Medical Association. 44 (2): 143–5. PMID 13449255.
  • ^ US 2897204, Frank A Cutler Jr FA, Chemerda JM, "Substituted piperidines and methods for making same", issued 28 July 1959, assigned to Merck and Co Inc 
  • ^ "Discontinued Prescription Drug Products". Canadian Pharmacists' Association. Archived from the original on 19 September 2008. Retrieved 28 July 2008.
  • ^ "Federal Register Notices: Quotas - 2014". Diversion Control Division, Drug Enforcement Agency. U.S. Department of Justice. 25 August 2014. Archived from the original on 4 March 2016. Retrieved 26 February 2016.
  • ^ "Pharmaceutical Information - LERITINE". RxMed. Retrieved 16 June 2010.
  • ^ "Anileridine Consumer Information". MedicineNet. Archived from the original on 28 March 2012. Retrieved 28 July 2008.



    • Stub icon

    This analgesic-related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Anileridine&oldid=1181417568"
    Categories: 
    ●4-Phenylpiperidines
     ●Phenethylamines
     ●Synthetic opioids
     ●General anesthetics
     ●Anilines
     ●Ethyl esters
     ●Mu-opioid receptor agonists
     ●Analgesics
     ●Analgesic stubs
     Hidden categories: 
    ●CS1 Brazilian Portuguese-language sources (pt-br)
     ●Articles with short description
     ●Short description is different from Wikidata
     ●Articles with changed EBI identifier
     ●Drugboxes which contain changes to verified fields
     ●All stub articles
      


    ●This page was last edited on 22 October 2023, at 22:33 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki